Stacie M. Jones, MD, Scott H. Sicherer, MD, A

Slides:



Advertisements
Similar presentations
A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,
Advertisements

Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy  Scott.
Advances in Diagnosing Peanut Allergy
Corinne A. Keet, MD, MS, Pamela A
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Theresa W. Guilbert, MD, David T. Mauger, PhD, David B
Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,
Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 
Alison M. Hofmann, MD, Amy M. Scurlock, MD, Stacie M
Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy  Michael Kulis, PhD, Katie.
Advances in food allergy in 2015
Cow's milk epicutaneous immunotherapy in children: A pilot trial of safety, acceptability, and impact on allergic reactivity  Christophe Dupont, MD, PhD,
Atopic dermatitis: Age and race do matter!
A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis  Donald Y.M. Leung, MD, PhD, Brett.
Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,
Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy  Pamela A. Frischmeyer-Guerrerio, MD,
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.
Food allergy: A practice parameter update—2014
A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response  Pooja Varshney, MD, Stacie.
Allergy testing in predicting outcome of open food challenge to peanut
A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy  Justin M. Skripak, MD, Scott D. Nash, MD, Hannah.
John Wei-Liang Tan, MD, FRACP, Carolina Valerio, BN, Elizabeth H
Advances in Diagnosing Peanut Allergy
Peter M. Wolfgram, MD, David B. Allen, MD 
Administration of a probiotic with peanut oral immunotherapy: A randomized trial  Mimi L.K. Tang, PhD, Anne-Louise Ponsonby, PhD, Francesca Orsini, MSc,
Theresa W. Guilbert, MD, David T. Mauger, PhD, David B
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
A. Wesley Burks, MD, Robert A. Wood, MD, Stacie M. Jones, MD, Scott H
Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors  Donald W. MacGlashan, MD, PhD,
Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S
Anna Nowak-Wegrzyn, MD, Katherine A. Bloom, MD, Scott. H
Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens  Brian P. Vickery, MD, Jing Lin, PhD, Michael Kulis, PhD, Zhiyan Fu,
The Editors’ Choice Journal of Allergy and Clinical Immunology
Epicutaneous immunotherapy for peanut allergy modifies IgG4 responses to major peanut allergens  Stef J. Koppelman, PhD, Aurélie Peillon, MSc, Wenceslas.
Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy  Yamini V. Virkud, MD, MA, MPH, A. Wesley Burks,
Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management  Scott H. Sicherer, MD, Hugh A. Sampson, MD  Journal.
A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity  Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,
Jennifer S. Kim, MD, Anna Nowak-Węgrzyn, MD, Scott H
Skin prick test to egg white provides additional diagnostic utility to serum egg white– specific IgE antibody concentration in children  Adina Kay Knight,
Corinne A. Keet, MD, MS, Pamela A
Cockroach allergens: Coping with challenging complexity
Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis  Thomas B. Casale, MD, William.
Influence of early-life exposures on food sensitization and food allergy in an inner-city birth cohort  Emily C. McGowan, MD, Gordon R. Bloomberg, MD,
Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment
House dust mite sublingual immunotherapy: Results of a US trial
Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy  Scott.
Brian P. Vickery, MD, Jelena P. Berglund, PhD, Caitlin M
Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,
Sublingual versus oral immunotherapy for peanut-allergic children: A retrospective comparison  Stacy J. Chin, MD, Brian P. Vickery, MD, Michael D. Kulis,
National prevalence and risk factors for food allergy and relationship to asthma: Results from the National Health and Nutrition Examination Survey  
Heather Lemon-Mulé, MD, Hugh A. Sampson, MD, Scott H
Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber 
Oral peanut immunotherapy in children with peanut anaphylaxis
Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy  Brian P. Vickery, MD, Amy M. Scurlock, MD, Michael Kulis,
The natural history of egg allergy in an observational cohort
Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch  Stacie M. Jones, MD, Wence K. Agbotounou,
Immune response to varicella vaccine in children with atopic dermatitis compared with nonatopic controls  Lynda Schneider, MD, Adriana Weinberg, MD, Mark.
Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G
The Editors' Choice Journal of Allergy and Clinical Immunology
Human basophils may not undergo modulation by DC-SIGN and mannose receptor– targeting immunotherapies due to absence of receptors  Mrinmoy Das, MSc, Caroline.
Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy  Stacie M. Jones, MD, A.
The natural history of milk allergy in an observational cohort
Personal and parental nativity as risk factors for food sensitization
Food allergy is associated with Staphylococcus aureus colonization in children with atopic dermatitis  Andrea L. Jones, MD, Douglas Curran-Everett, PhD,
Theresa W. Guilbert, MD, David T. Mauger, PhD, David B
Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization  Edwin H. Kim, MD, J. Andrew Bird, MD, Michael Kulis,
The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy  Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.
Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease  Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,
The Editors’ Choice Journal of Allergy and Clinical Immunology
The Editors' Choice Journal of Allergy and Clinical Immunology
Presentation transcript:

Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults  Stacie M. Jones, MD, Scott H. Sicherer, MD, A. Wesley Burks, MD, Donald Y.M. Leung, MD, Robert W. Lindblad, MD, Peter Dawson, PhD, Alice K. Henning, MS, M. Cecilia Berin, PhD, David Chiang, MSc, Brian P. Vickery, MD, Robbie D. Pesek, MD, Christine B. Cho, MD, Wendy F. Davidson, PhD, Marshall Plaut, MD, Hugh A. Sampson, MD, Robert A. Wood, MD  Journal of Allergy and Clinical Immunology  Volume 139, Issue 4, Pages 1242-1252.e9 (April 2017) DOI: 10.1016/j.jaci.2016.08.017 Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 CONSORT diagram. Enrollment and randomization of younger participants aged 4 to less than 6 years was conducted as in the full study population, as indicated. Enrollment was paused after the first 10 participants were enrolled for a predetermined interim DSMB safety review after 35 days (21 days of escalation and 14 days of maintenance) of dosing to ensure tolerability of the study product. Because of completed study enrollment, no further participants in the 4- to less than 6-year-old age range were enrolled after the DSMB review. Journal of Allergy and Clinical Immunology 2017 139, 1242-1252.e9DOI: (10.1016/j.jaci.2016.08.017) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 SCD from baseline to the week 52 OFC. A, Analysis by treatment group. B, Analysis by age and treatment group. Top panels represent the 4- to 11-year-old age group. Bottom panels represent the greater than 11-year-old age group. Solid lines represent median values, and hatched lines represent the upper and lower IQR. Journal of Allergy and Clinical Immunology 2017 139, 1242-1252.e9DOI: (10.1016/j.jaci.2016.08.017) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Immune mechanistic assessments over time by treatment group. A, Change in peanut-specific IgE levels over time. No significant differences over time were seen between treatment groups (P = .37). B, Change in peanut-specific IgG4 levels over time. A significant difference over time was seen between treatment groups (P < .0001), with a larger increase noted among the active Viaskin Peanut groups compared with the placebo group. C, Change in the peanut IgG4/IgE ratio over time. A significant difference over time was seen between treatment groups (P < .0001), with a larger increase noted among the active Viaskin Peanut groups compared with the placebo group. Solid lines represent median values, and hatched lines represent the upper and lower IQR. Journal of Allergy and Clinical Immunology 2017 139, 1242-1252.e9DOI: (10.1016/j.jaci.2016.08.017) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 SPT results over time by treatment group. No significant difference was noted among treatment groups over time; however, when examined within a treatment group, a decrease in SPT size was noted in the VP250 group (P = .02). Solid lines represent median values, and hatched lines represent the upper and lower IQR. Journal of Allergy and Clinical Immunology 2017 139, 1242-1252.e9DOI: (10.1016/j.jaci.2016.08.017) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Effect of peanut EPIT on basophil activation (percentage of CD63+ basophils) over time by treatment group. Top row, Placebo group; middle row, VP100 group; bottom row, VP250 group. Cells were stimulated with 0.001 μg/mL peanut extract (column 1), 0.01 μg/mL peanut extract (column 2), 0.1 μg/mL peanut extract (column 3), or 1 μg/mL peanut extract (column 4). Significant differences over time were observed only at a stimulation dose of 0.01 μg of peanut extract (P < .0001) when evaluating for a global treatment effect. Diamonds represent mean values. Journal of Allergy and Clinical Immunology 2017 139, 1242-1252.e9DOI: (10.1016/j.jaci.2016.08.017) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions